Tumor growth relies upon the production of new blood vessels, also known as angiogenesis, to supply adequate oxygen and nutrients to the cells. Angiogenesis blockade therapy was thus developed to impair blood vessel growth and cut off this supply. This is accomplished with the use of medicines targeting pro-angiogenic factors such as vascular-endothelium growth factor (VEGF), fibroblast growth factor (FGF), and stem cell factor (SCF). For example, bevacizumab is a monoclonal antibody that targets VEGF and has shown promise in combating non-small-cell lung cancer, but the use of angiogenesis inhibitors has also been linked to an increase in local tumor invasiveness and the spread of cancer to other parts of the body. New evidence suggests that these issues can be diminished by administering anti-angiogenic agents in combination with other strategies. Immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy can improve the immune system’s ability to recognize and eradicate cancer cells, and the changes to tumor vasculature induced by anti-angiogenic agents may improve the delivery of chemotherapeutic and radiotherapeutic agents. Future studies looking at the effects of these and new combination treatments will provide novel insights into the development of new cancer treatment strategies and advance the fight against cancer.